Researchers at The University of Kansas Cancer Center have secured a $3.6 million grant from the U.S. Department of Defense to study high-dose intravenous Vitamin C for treating muscle-invasive bladder cancer. This type of cancer occurs when cancer cells spread to the muscle layer of the bladder wall.
Anthony Sung, MD, has been named the A. Drue Jennings Professor in Medical Oncology and the director of the Center for Survivorship and Patient-Oriented Research at The University of Kansas Cancer Center.
The Kansas Institute for Precision Medicine (KIPM) will continue its mission to improve health care by training physicians and scientists in precision medicine and supporting their research, thanks to a renewed Centers of Biomedical Research Excellence (COBRE) award from the National Institute of General Medical Sciences, part of the National Institutes of Health.
Benyi Li, MD, PhD, professor in the Department of Urology and member of The University of Kansas Cancer Center, has received a nearly $1.4 million grant from the U.S. Department of Defense to develop a short peptide-based therapy for prostate cancer patients.
Pool Cool is a program designed to educate young people in The University of Kansas Cancer Center’s catchment area on sun safety behaviors.
A researcher at The University of Kansas Cancer Center has received a $930,000 grant from the U.S. Department of Defense to study a new targeted therapy option for people diagnosed with ductal carcinoma in situ (DCIS).
In order to grow and train future clinical and translational scientists, The University of Kansas Cancer Center has received a $2.4 million grant from the National Cancer Institute (NCI).
The University of Kansas Cancer Center has received a $100 million lead gift to build a new, state-of-the-art destination cancer center. This gift is both the largest gift ever given by the Sunderland Foundation and the largest ever received by the University of Kansas and The University of Kansas Health System.
Chimeric antigen receptor (CAR) T-cell therapy amplifies the immune system’s ability to recognize and kill cancer cells. The first CAR T-cell therapy was approved by the Food and Drug Administration (FDA) in 2017. Today, there are 6 FDA-approved CAR-based therapies to treat certain types of leukemia, lymphoma and myeloma, all of which are available at The University of Kansas Cancer Center.
The mural, designed in collaboration with members of organizations in the surrounding urban community, is one part of the The University of Kansas Cancer Center’s broader campaign to increase the participation of minority and underserved populations in clinical trials.
TEAMSPORT will create a standardized approach to ordering genomic tests and adapt it for use in community cancer centers, where most cancer patients receive testing and treatment.
Joint call to action urges individuals, providers and insurers to increase access to and utilization of low-dose CT screening for those at high risk for lung cancer.
Kansas Governor Laura Kelly has proclaimed September “Comprehensive Cancer Centers Awareness Month” in recognition of The University of Kansas Cancer Center becoming designated as a “Comprehensive” cancer center by the National Cancer Institute (NCI).
Individuals with blood-related cancers are more likely to experience a COVID-19 infection even after being vaccinated, a University of Kansas Cancer Center study has found.
The University of Kansas Cancer Center has been designated as a “Comprehensive” cancer center by the National Cancer Institute (NCI). This is the highest level of recognition awarded by the NCI and is the gold standard for cancer centers.
Researchers at The University of Kansas Cancer Center have released the results of a clinical trial that examined the effectiveness of varenicline in African Americans. In their study published in JAMA, African American daily smokers who were given varenicline while receiving counseling had significantly greater quit rates than those who received a placebo.
About 95% of participants achieved a measurable immune response after vaccination, according to study published in JAMA Oncology.
A three-year $1.2 million Breakthrough Award grant from the Department of Defense will help researchers identify tailored treatments for people with triple-negative breast cancer. Priyanka Sharma, MD, breast medical oncologist, and Shane Stecklein, MD, PhD, radiation oncologist, will lead the project.
Ten years ago, on Jan. 23, 2012, the brand-new University of Kansas Clinical Research Center opened its doors.
.jpg&width=400&height=400)
Axicabtagene ciloleucel, known by the brand name Yescarta, is significantly more effective than the current standard of care in treating people with large B-cell lymphoma who relapse after the first line of treatment.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
